Abstract

Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2207-2209.e3.doi: 10.1016/j.cgh.2020.10.025. Epub 2020 Oct 14.

Marc Fenster 1, Quazim A Alayo 2, Aava Khatiwada 3, Wenfei Wang 4, Christina Dimopoulos 5, Alexandra Gutierrez 3, Matthew A Ciorba 3, George P Christophi 6, Robert P Hirten 7, Christina Ha 8, Poonam Beniwal-Patel 9, Benjamin L Cohen 10, Gaurav Syal 8, Andres Yarur 9, Anish Patel 11, Jean-Frederic Colombel 7, Joel Pekow 4, Ryan C Ungaro 7, David T Rubin 4, Parakkal Deepak 12

 
     

Author information

  • 1Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
  • 2Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri; Division of Internal Medicine, St. Luke's Hospital, St. Louis, Missouri.
  • 3Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri.
  • 4University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois.
  • 5Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • 6Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri; Steward Center for Inflammatory Bowel Diseases, Rockledge, Florida; University of Central Florida College of Medicine, Orlando, Florida.
  • 7Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • 8Division of Digestive and Liver Diseases, Cedars Sinai Medical Center, Los Angeles, California.
  • 9Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • 10Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Gastroenterology, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.
  • 11Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas.
  • 12Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri.

Abstract

The safety and efficacy of tofacitinib in Crohn's disease (CD) has been studied in 2 phase II trials in patients with moderate-to-severe CD with no new safety signals observed, but no significant difference from placebo in the primary efficacy endpoint of clinical response.1-3 However, post hoc analyses and smaller studies have observed clinical and biologic response to tofacitinib in patients with CD.2,4,5 There is a paucity of real-world effectiveness and safety data for tofacitinib in non-Food and Drug Administration label usage in patients with CD and patients with inflammatory bowel disease-unclassified (IBD-U).

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.